Patents Assigned to TLC Biopharmaceuticals, Inc.
  • Patent number: 10391056
    Abstract: The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: August 27, 2019
    Assignees: Taiwan Lipsome Company, LTD., TLC Biopharmaceuticals, Inc.
    Inventors: Pei Kan, ChiaHung Hung, KeeIung Hong, Yun-Long Tseng, Yung-Hsu Chan
  • Publication number: 20190216932
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Application
    Filed: January 7, 2019
    Publication date: July 18, 2019
    Applicants: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Pei KAN, Yun-Long TSENG, Han-Chun OU, Chun-yen LAI
  • Patent number: 10350294
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10322086
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 18, 2019
    Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Patent number: 10286076
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: May 14, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10220095
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: March 5, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD, TLC BIOPHARMACEUTICALS, INC
    Inventors: Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
  • Patent number: 10058616
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: August 28, 2018
    Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 9987360
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: June 5, 2018
    Assignees: TAIWAN LIPOSOME CO. LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Patent number: 9789062
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: October 17, 2017
    Assignees: TLC BIOPHARMACEUTICALS, INC., TAIWAN LIPOSOME COMPANY, LTD.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Publication number: 20170266295
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 21, 2017
    Applicants: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Pei KAN, Yun-Long TSENG, Han-Chun OU, Chun-yen LAI
  • Patent number: 9700511
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent. The present invention also relates to methods of inhibiting cancer cell growth, comprising administering the pharmaceutical composition described herein.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: July 11, 2017
    Assignees: TLC Biopharmaceuticals, Inc., Taiwan Liposome Company, Ltd.
    Inventors: Pei Kan, Yun-Long Tseng, Han Chun Ou
  • Patent number: 8956600
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: February 17, 2015
    Assignees: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Publication number: 20140287025
    Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.
    Type: Application
    Filed: April 9, 2014
    Publication date: September 25, 2014
    Applicants: Taiwan Liposome Company, TLC Biopharmaceuticals, Inc.
    Inventors: Jun-Jen LIU, Yun-Long Tseng, Sheue-Fang SHIH, Luke S.S. GUO, Keelung HONG
  • Publication number: 20140193486
    Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 10, 2014
    Applicants: TLC Biopharmaceuticals, Inc., Taiwan Liposome Company
    Inventors: Jun-Jen LIU, Yun-Long Tseng, Sheue-Fang SHIH, Luke S.S. GUO, Keelung HONG
  • Patent number: 8753673
    Abstract: The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component able to form a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction; wherein the liposome composition comprising the therapeutic agent has a mean particle diameter of about 30 to 200 nm and may accumulate at the neovascularization sites of the eyes 24 hours after the intravenous administration of the liposome composition comprising the therapeutic agent to the patient. A method for delivering the therapeutic agent to the eyes in a patient with this liposome composition is also provided.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: June 17, 2014
    Assignees: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Jun-Jen Liu, Chi-Chun Lai, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Publication number: 20140135357
    Abstract: The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 15, 2014
    Applicants: Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Yun-Long TSENG, Keelung HONG, Min-Wen KUO
  • Patent number: 8168648
    Abstract: The present invention provides two new camptothecin derivatives, which were identified as S,R- and S,S-topotecan lactates, respectively. Both compounds have anticancer activities. Pharmaceutical compositions of the new camptothecin derivatives, and cancer therapies with the new camptothecin derivatives or their pharmaceutical compositions were also provided.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: May 1, 2012
    Assignees: Taiwan Liposome Co., Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Min-Wen Kuo, Yung-Hsu Chan, Yun-Long Tseng, Siong-Tern Liew, Keelung Hong
  • Publication number: 20100227877
    Abstract: The present invention provides two new camptothecin derivatives, which were identified as S,R- and S,S-topotecan lactates, respectively. Both compounds have anticancer activities. Pharmaceutical compositions of the new camptothecin derivatives, and cancer therapies with the new camptothecin derivatives or their pharmaceutical compositions were also provided.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 9, 2010
    Applicants: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Min-Wen Kuo, Yung-Hsu Chan, Yun-Long Tseng, Siong-Tern Liew, Keelung Hong
  • Patent number: 7740844
    Abstract: The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: June 22, 2010
    Assignees: Taiwan Liposome Co. Ltd, TLC Biopharmaceuticals, Inc.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Hsiu-Li Song, Po-Chun Chang, Sheue-Fang Shih
  • Publication number: 20090269336
    Abstract: The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.
    Type: Application
    Filed: April 29, 2008
    Publication date: October 29, 2009
    Applicants: Taiwan Liposome Co. Ltd, TLC Biopharmaceuticals, Inc.
    Inventors: Keelung Hong, Luke S.S. Guo, Yun-Long Tseng, Hsiu-Li Song, Po-Chun Chang, Sheue-Fang Shih